Marion Couderc

Marion Couderc

Auto-generated profile, based on publicly available information

Marion Couderc

Rheumatology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2014 in The Journal of Rheumatology
Verified
Journal Article
Closed access
FAFaisal Aljuhani
Faisal Aljuhani
ATAnne Tournadre
Anne Tournadre
ZTZuzana Tatar
Zuzana Tatar
MCMarion Couderc
Marion Couderc
SMSylvain Mathieu
Sylvain Mathieu
JDJean-Jacques Dubost
Jean-Jacques Dubost
Objective.: The SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis) is a rare disease and only a few series have been published about it. We describe the experience of a rheumatology department with a focus on the therapeutic aspects.Methods.: All cases of SAPHO fulfilling the Benhamou criteria and seen between 1992 and 2013 in our unit were retrospectively included.Results.: Forty-one patients (11 men and 30 women) were included. The average age was 45 years (20–80 yrs) at the time of diagnosis. Nineteen patients had palmoplantar pustulosis, 3 had psoriasis vulgaris, 3 had severe acne, and 15 had no dermatological involvement. Bone symptoms involved mainly the anterior chest wall (n = 28, 68%), followed by the spine (n = 16, 39%) and sacroiliac joints (n = 12, 29%). Four patients had peripheral osteitis and 2 had mandibular osteitis. Ten patients had peripheral arthritis affecting mainly the knees and wrists. None of the 36 patients tested was HLA-B27–positive. At least a partial response was achieved with colchicine, methotrexate, or sulfasalazine in 0/6, 2/4, and 1/6 of patients, respectively. Antibiotic therapy (azithromycin, n = 7; doxycycline, n = 2) was effective in 2/9 patients. Pamidronate was prescribed in 26 patients with bone involvement and 18/22 patients evaluable at 6 months responded to this therapy. Two patients were treated with tumor necrosis factor blockers: 1 with infliximab and 1 with adalimumab, followed by etanercept.Conclusion.: Based on our experience, SAPHO can be diagnosed in the elderly. It was not associated with HLA-B27. Soft tissue involvement was common and the bisphosphonates were generally effective on bone involvement.

1 October 2014 in Joint Bone Spine
Verified
Journal Article
Closed access
JDJean-Jacques Dubost
Jean-Jacques Dubost
MCMarion Couderc
Marion Couderc
ZTZuzana Tatar
Zuzana Tatar
ATAnne Tournadre
Anne Tournadre
JLJulien Lopez
Julien Lopez
MSMartin Soubrier
Martin Soubrier

1 November 2019 in Joint Bone Spine
Verified
Journal Article
Closed access
SMSylvain Mathieu
Sylvain Mathieu
MCMarion Couderc
Marion Couderc
ATAnne Tournadre
Anne Tournadre
MSMartin Soubrier
Martin Soubrier

20 January 2023 in Infectious Diseases Now
Verified
Journal Article
Closed access
MLM. Lacasse
M. Lacasse
SDS. Derolez
S. Derolez
EBEric BONNET
Eric BONNET
AAA. Amelot
A. Amelot
BBB. Bouyer
B. Bouyer
VZValerie Zeller
Valerie Zeller

22 October 2011 in Rheumatology
Verified
Journal Article
Open access
PDF file
MCMarion Couderc
Marion Couderc
JGJacques-Eric Gottenberg
Jacques-Eric Gottenberg
XMXavier Mariette
Xavier Mariette
EHEric Hachulla
Eric Hachulla
JSJean Sibilia
Jean Sibilia
MSMartin Soubrier
Martin Soubrier
Objectives. To assess the efficacy and safety of rituximab (RTX) in patients with refractory idiopathic inflammatory myopathies (IIMs). Methods. RTX efficacy was based on improvement in three criteria: creatine phosphokinase (CPK) level, daily CS dose and physicians’ opinion. A decrease in CPK level or CS dose was significant if it was >25%. Results. Thirty patients were studied (21 women; age 52.5 years, disease duration 6.1 years). All had previously received immunosuppressors (ISs). Twenty-five patients received 1 g of RTX twice 2 weeks apart and five received 4 weekly RTX infusions (375 mg/m2). RTX was given in association with IS in 21 patients. Twenty-eight patients received CS (mean dose 21.2 mg/day). Mean follow-up was 17.2 months. Thirteen adverse events were reported, including seven infections and one serious infection (pyelonephritis). RTX was effective in 16 patients. Duration of efficacy was 15.5 months. Of the 20 patients with baseline CPK level ≥2 × upper limit of normal (ULN), 11 (55%) improved. The main level fell from 20.7 to 11 × ULN. CS decreased in 15 patients, stopped in 4, remained stable in 8 and increased in the remaining 3. The CS dose decreased from 21.2 to 9.9 mg/day. The physicians’ opinion was favourable in 21 patients. Manual muscle testing was performed in only five patients: it increased from 87 to 91/100 at 6 months. Conclusions. RTX was well tolerated and had some beneficial effects on patients with IIM, the main limitation of this study resulted in a lack of manual muscle testing.

1 August 2017 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
AFAngelique Fan
Angelique Fan
BPBruno Pereira
Bruno Pereira
ATAnne Tournadre
Anne Tournadre
ZTZuzana Tatar
Zuzana Tatar
SMSandrine Malochet-Guinamand
Sandrine Malochet-Guinamand
JDJean-Jacques Dubost
Jean-Jacques Dubost